FDA Approves ARAZLO (Tazarotene) Lotion For Acne Vulgaris

FDA Approves Ortho's New Acne Topical

The U.S. Food and Drug Administration has approved the New Drug Application for Ortho Dermatologics’ ARAZLO (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older. ARAZLO is the first tazarotene acne treatment available in a lotion form, and has been shown to provide strong efficacy with favorable tolerability.

Stoll Joins Soliton as Senior Director of Clinical Development

Rapid Acoustic Pulse Device

Mary Stoll is the new senior director of clinical development Soliton, a medical device manufacturer with a novel and proprietary acoustic pulse platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center. Stoll will be responsible for direct oversight of all clinical activities of the company’s Rapid Acoustic Pulse (RAP) device for tattoo removal, improvement in the appearance of cellulite and keloid scarring, and additional pipeline indications.

Simplified Tear Trough Injections

HA Fillers for Undereye Volume Loss

In the December 2019 issue of the Journal of Cosmetic Dermatology, Syed N. Hussain, MD, DNB, et al, shared a new method to simplify filler injections to the tear trough. The “Tick Method” involves performing three small bolus injections of hyaluronic acid in defined anatomical regions using BD insulin syringes with fixed 6mm 31G needles.

Consensus Guidelines on Opioid Prescribing Practices in Dermatology

Pill Bottle

A group of 40 board-certified dermatologists, including Mohs micrographic surgeons, dermatopathologists and cosmetic dermatologists have developed consensus recommendations for opioid management following some of the most common dermatologic procedures. These procedure-specific recommendations were published the Journal of the American Academy of Dermatology (online November 18, 2019)

The panel developed recommendations for 87 of the most common dermatologic procedures, measured by morphine milligram equivalents (MME) and determined that:

Revance DAXI Takes Next Step Toward FDA Approval

Revance Files BLA for DAXI

Revance Therapeutics has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines. The submission includes results from the three SAKURA Phase 3 trials in which DAXI demonstrated that half of the patients treated maintained none or only mild frown lines for at least 24 weeks (approximately six months) after a single treatment.

Baring To Acquire Lumenis

Top Aesthetic Laser Provider Sold

Baring Private Equity Asia (BPEA) has agreed to acquire Lumenis, a provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an enterprise value of over $1 billion.

Lumenis has a presence in over 100 countries and close to 1,500 employees worldwide. The Asia Pacific region is its largest market, together with a strong presence in North America and EMEA.

Hologic to Sell Cynosure to Clayton, Dubilier & Rice

Hologic has entered into a definitive agreement to sell Cynosure to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. Under the terms of the agreement, approximately 825 employees will transfer with the Cynosure business. The transaction is expected to close around the end of calendar 2019, subject to regulatory approvals and other customary conditions.